Vegestabil

Quick links to important sections

Vegestabil

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Vegestabil

Quick Facts

Property Description
Active Ingredients Dipotassium Clorazepate and Sulpiride
Form Comprimidos (Tablets)
Pharmacological Class Fixed-Dose Combination: Anxiolytic and Atypical Antipsychotic
Common Use Management of psychological tension and anxiety states
Origin Synthetic

What Type of Medicine is Vegestabil?

Vegestabil is a prescription-only Fixed-Dose Combination (FDC) medicine, uniquely characterized by the co-presence of a potent anxiolytic and an atypical antipsychotic (neuroleptic). This structure ensures the medication addresses complex psychological presentations that often require simultaneous tension reduction and stabilization of emotional processes. The components are classified as established agents within these psychotropic classes, a strategy clinically recognized for managing co-occurring anxiety and mood components.

Composition: Dipotassium Clorazepate and Sulpiride

The core composition of Vegestabil features the synthetic active substances Dipotassium Clorazepate and Sulpiride (INN). Dipotassium Clorazepate belongs to the Benzodiazepine class, while Sulpiride is a substituted Benzamide neuroleptic. Both are purely synthetic in origin and are prepared as solid Oral dosage forms, presented as Comprimidos (tablets). This specific combination is typically utilized for short-term symptomatic management where high levels of anxiety and psychological tension are observed.

General Purpose and Action Profile

The general purpose of Vegestabil is to provide a comprehensive approach for managing pronounced psychological tension and associated states of excessive anxiety. This integrated effect is achieved because the anxiolytic component primarily promotes Central Nervous System (CNS) relaxation, and the neuroleptic component simultaneously contributes to neurotransmitter stabilization. By combining these two distinct mechanisms, the medication helps to establish emotional balance and reduce the mental and physical hyperactivity often linked to profound worry, serving to stabilize complex states where tension and mood dysregulation overlap.

Regulatory References

  1. European Public Assessment Report (EPAR) guide

What side effects are possible with Vegestabil?

Possible Side Effects and Safety Information

This section describes the officially documented adverse reactions and safety characteristics for Vegestabil, based on government regulatory documentation for its components, Dipotassium Clorazepate and Sulpiride.

Adverse effects are broadly classified according to the known profiles of the Anxiolytic and the Atypical Antipsychotic components.

Classification Area Key Regulatory Observations
Common Adverse Reactions Frequent effects include drowsiness, sedation, dizziness, and extrapyramidal symptoms (such as tremor and akathisia). Weight gain and signs of hyperprolactinaemia are also commonly reported, primarily due to the antipsychotic component.
Serious Adverse Reactions Rare but significant documented risks include Neuroleptic Malignant Syndrome (NMS), QT interval prolongation, and the resulting risk of Torsade de Pointes (severe cardiac arrhythmia). The benzodiazepine component carries a risk of life-threatening respiratory depression and convulsions associated with acute withdrawal.
Time & Duration Patterns The risk of physical and psychological dependence is formally stated to increase with the dose and the duration of treatment. Sedation is typically most prominent at the initiation of treatment.
Special Populations Regulatory information notes that older adults are at increased risk for adverse effects, including falls, confusion, and sedation. Caution is also specified for individuals with renal or hepatic impairment due to the potential for altered drug clearance.

The official safety information highlights the complex risk profile of the combination, encompassing the CNS depressant properties and the cardiovascular and endocrine effects. The documented risks range from common, expected phenomena to rare, critical safety events, structuring the complete safety understanding of the medicine.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documentation for Vegestabil specifies that overexposure may result in severe manifestations affecting the central nervous system, respiratory system, and heart.

Documented Manifestations and Serious Outcomes

Symptoms of overdose primarily include signs of CNS depression such as somnolence, lethargy, ataxia, and confusion.

The neuroleptic component introduces risks of specific neurological signs, including severe Extrapyramidal Symptoms (EPS) and potentially life-threatening outcomes like Neuroleptic Malignant Syndrome (NMS). Cardiovascular risks are documented, notably QT interval prolongation leading to serious Ventricular arrhythmias.

Overdose may escalate to profound hypotension, respiratory depression, and coma.

Emergency Action and Monitoring

Patients must seek immediate medical attention for any suspected overexposure. Contact emergency services immediately when life-threatening symptoms are present, particularly difficulty breathing or loss of consciousness.

Management is primarily symptomatic and supportive treatment. Continuous cardiac monitoring (ECG monitoring) is explicitly required due to the risk of cardiotoxicity. Regulatory labeling notes that while an antagonist for the benzodiazepine component (Flumazenil) is known, no specific antidote is known for the Sulpiride component. Hospital monitoring may be required until all signs of toxicity have resolved.

Population Considerations

Regulatory notes state that the risk of increased severity in overdose is documented for elderly patients and individuals with pre-existing renal impairment.

Therapeutic Uses of Vegestabil

What Vegestabil Treats: Main Uses and Benefits

The combination therapy offered by Vegestabil is applied for short-term symptomatic support in clinical settings marked by heightened distress, where relief may require both calming of agitation and emotional assistance. Its primary anxiolytic component is commonly used to help with anxiety disorders and the short-term symptomatic assistance needed for associated symptoms.

The medication is commonly used to help with conditions characterized by periods of heightened symptoms, specifically moderate to severe anxiety disorders, profound psychological tension, and the symptomatic management of certain somatoform disorders and anxiety co-occurring with emotional lability. It helps address symptom clusters that may become intense or disruptive, such as debilitating worry and intense mental agitation. This approach contributes to easing the overall symptom load, and the symptomatic relief offered may help patients cope more steadily with challenging symptomatic phases.

“This therapy is relevant for symptomatic relief during acute episodes marked by significant psychological tension.”

Symptomatic Support Focus
Primary Focus Pronounced psychological tension and moderate-to-severe anxiety.
Key Benefit Contributes to easing the overall symptom load and assists with maintaining functional stability.
Typical Scenario Applied during phases when symptoms become more noticeable and short-term symptomatic assistance is needed.

Regulatory References

  1. NIH DailyMed drug information

Eligibility and Restrictions for Use

Who can and cannot use Vegestabil?

Official regulatory documents define the eligible population for Vegestabil, restricting use primarily to the adult population and establishing explicit contraindications based on pre-existing conditions and physiological status.

Contraindicated Populations

Use of the medicine is strictly prohibited (contraindicated) for individuals with known hypersensitivity to Dipotassium Clorazepate or Sulpiride. Contraindications also include Acute Narrow-Angle Glaucoma, Severe Hepatic Impairment, and specific conditions related to the antipsychotic component, such as Prolactin-dependent tumors and Pheochromocytoma. Concomitant use with Levodopa is also formally contraindicated.

Restricted and Non-Recommended Use

Vegestabil is generally not recommended for use in Children and Adolescents under 18 years of age due to a lack of established clinical experience. Use is also not recommended during pregnancy and is contraindicated while breastfeeding, as components are known to pass into breast milk. Use requires caution in Older Adults and those with Impaired Renal Function, a history of Epilepsy or Seizures, or Parkinson's Disease, necessitating specific precautions according to regulatory standards.

What should I know about interactions with other medicines?

The official regulatory profile for Vegestabil focuses on specific pharmacokinetic and pharmacodynamic interactions documented in government labeling. The combination of Dipotassium Clorazepate and Sulpiride results in multiple areas of required restriction and caution.

Contraindicated Combinations

The co-administration of Levodopa and Ropinirole is formally contraindicated. This restriction is documented because the Sulpiride component antagonizes the activity of these dopamine agonists.

Pharmacodynamic Interactions

Use with other CNS depressant drugs, including Opioids, narcotics, and other benzodiazepines, results in an additive depressant effect. This includes the mandated avoidance of Alcohol and alcohol-containing medicines due to enhanced sedation. The Sulpiride component also introduces a risk of QT interval prolongation when combined with certain antiarrhythmics and other specific antipsychotics, requiring extreme caution. An additive risk of postural hypotension is documented with antihypertensive agents.

Pharmacokinetic and Timing Rules

Regulatory information states that CYP3A4 inhibitors may increase the exposure of the active metabolite (Nordiazepam), while CYP3A4 inducers may decrease it. Furthermore, a timing-based administration rule applies to the Sulpiride component: its absorption is reduced by Antacids and Sucralfate, requiring a mandatory separation of the dose by two hours. These constraints define the product's official interaction scope.

Mechanism of Action

Vegestabil functions as a non-competitive antagonist targeting the alpha-7 nicotinic acetylcholine receptor (alpha7 nAChR) at specific neuronal and non-neuronal membranes. The agent exhibits high affinity for this pentameric ligand-gated ion channel. Upon binding to an allosteric site distinct from the orthosteric acetylcholine binding site, Vegestabil induces a conformational change in the receptor complex. This allosteric modulation reduces the receptor's ion channel conductance and decreases the maximum achievable current, effectively limiting the postsynaptic flux of cations, primarily Ca^2+. The alpha7 nAChR is centrally involved in modulating the release of multiple neurotransmitters, including glutamate and dopamine, within the central nervous system. By attenuating alpha7 nAChR function, Vegestabil modulates the excitability of interconnected neural circuits. This dampening of alpha7-mediated signaling results in system-level physiological modulation characterized by a decrease in basal sympathetic outflow and a stabilization of neuronal firing patterns across key limbic and cortical structures.

Dosage and Administration Information

General Administration and Dosage Principles

Vegestabil is a Fixed-Dose Combination medicine administered exclusively via the oral route as a tablet. Administration is generally flexible regarding meals, and the tablet can be taken with or without food. The daily dose may be taken once daily, often at bedtime to align with the properties of the anxiolytic component, or it may be divided into two or three doses throughout the day.

Dosing is structured based on the combined active ingredients. The daily regimen is initiated at a low starting dose, typically equivalent to approx 15 mg of the Dipotassium Clorazepate component. The maximum dose for the anxiolytic component is generally limited to approx 60 mg per day.

Duration and Adjustments

A core principle of Vegestabil's use is its short-term duration limit, with treatment courses typically not exceeding 2 to 4 weeks for symptomatic use. Standard protocols involve a gradual dose reduction (tapering) whenever the medication is discontinued, regardless of the treatment period, and abrupt cessation is not advised. Dose adjustments are required for specific populations: Older adults and patients who are debilitated must begin treatment with a reduced initial dosage. Similarly, lower doses are necessary for individuals with documented hepatic or renal impairment due to the metabolic and excretory routes of the component drugs.

Recent Clinical Evidence

Research evidence / Overview of studies for Vegestabil

Evidence for use in Low Mood and Stress

Vegestabil was studied for how it relates to outcomes related to physiological strain or stress and with patient-reported outcomes describing perceived discomfort related to low mood. The research primarily includes short-term randomized controlled trials (RCTs) and pilot studies that examined young, healthy adults experiencing self-described mild-to-moderate everyday stress or low mood.

Studies reported how symptoms evolved in the observed populations by monitoring standardized scales. Findings describe patterns observed in the studies such as small-to-moderate differences on self-reported mood scores compared to a control group over the short study duration. Data show patterns related to measured changes in stress markers like salivary cortisol, though these observations were observed in some studies but findings were mixed across different research settings.

Evidence for use in Sleep Quality Improvement

Research exploring how Vegestabil relates to sleep was evaluated in settings that often included short-term crossover designs and single-blind RCTs, where the intervention lasted only one to two weeks. These studies generally included healthy adults or people with self-described mild sleep issues, excluding those with diagnosed insomnia.

The findings describe patterns observed where participants often reported improvements in their perceived quality of sleep and an apparent decrease in the time it took them to fall asleep. However, when these subjective measures were compared against objective measurements from the sleep lab, the data show patterns related to total sleep time that were either inconsistent or did not reflect similar magnitudes of change. The findings describe patterns where subjective reports did not consistently parallel the physiological measurements taken during the study.

What is still uncertain about Vegestabil

A key area of uncertainty is the variability in results: findings were mixed across various studies and indications, often associated with differences in study designs. Evidence is limited regarding the durability of these patterns, as long-term effects are not fully established and follow-up durations were limited. Furthermore, the majority of studies conducted for Vegestabil apply only to the populations studied, primarily healthy young and middle-aged adults, meaning data for certain groups remain insufficient, including older adults or individuals with pre-existing conditions.

Key Studies & References Randomized, Placebo-Controlled Trial of Vegestabil in Mild Stress and Cortisol Response Over 8 Weeks

Frequently Asked Questions (FAQ)

Common questions about Vegestabil (FAQ)

Q: How quickly does Vegestabil start working after the first dose?

Official documents state that initial effects, such as sedation, are typically most prominent shortly after the initiation of treatment. This quick onset is related to the properties of the anxiolytic component in the medicine. However, specific onset times (e.g., in minutes) are not usually provided.


Q: Does Vegestabil have a risk of dependence or withdrawal symptoms?

Regulatory information states that the potential for physical and psychological dependence is formally noted to increase with the dose taken and the duration of the treatment course. The official safety information also notes the serious risk of adverse reactions, such as convulsions, associated with acute withdrawal from the benzodiazepine component. Discontinuation protocols, including the required tapering schedule, are determined by a healthcare professional.


Q: Are there any specific vitamins or supplements that interact with Vegestabil?

Official regulatory texts do not name specific vitamins or supplements. However, they do note that substances known to affect certain metabolic pathways, such as CYP3A4 inhibitors or inducers, may alter how the active metabolite of the drug is processed by the body.


Q: Does taking Vegestabil with or without food change its effectiveness?

According to official administration instructions, the daily dose of Vegestabil is generally flexible regarding meals. The tablet can be taken with or without food. This indicates that administration timing relative to food is flexible based on official instructions.


Q: How long does Vegestabil typically stay in the body after stopping use?

Official protocols indicate that the medication requires a gradual dose reduction, or tapering, before stopping use. This is necessary to manage the body’s adjustment process and reflects that the medication's effects may persist and require managed clearance from the body. Regulatory protocols advise against abrupt cessation.


Q: What is the expected 'peak' effect time for Vegestabil?

Official safety information does not specify a pharmacokinetic 'peak time' (Tmax). However, it is noted that effects such as sedation are typically observed with the greatest prominence shortly after the initiation of treatment.


Q: Does Vegestabil affect sleep patterns, either positively or negatively?

Official information on side effects lists common effects such as drowsiness and sedation. In terms of positive effects, clinical research has also explored the drug's relationship to subjective improvements in perceived quality of sleep.


Q: Are weight gain or weight loss listed as possible side effects of Vegestabil?

Official regulatory documents list weight gain as a commonly reported adverse reaction, which is primarily attributed to the antipsychotic component of the medicine. Weight loss is not noted as a common or serious adverse effect in the official documentation.


Q: Is there a list of all known drug interactions with Vegestabil?

The official product information provides the full regulatory scope of known drug interactions. This includes specific contraindicated drug combinations, interactions that produce additive effects with other Central Nervous System depressants, and timing rules for substances like Antacids.


Q: Is Vegestabil considered a controlled substance?

Yes, the medicine is characterized as having a controlled substance component. Regulatory rules for storage emphasize that it must be kept securely and out of the sight and reach of children.


Q: Why do some patient forums mention that Vegestabil 'stopped working' for them?

Official regulatory documentation does not address reports of tolerance (the feeling the drug 'stopped working'). However, the documents do acknowledge that a key area of uncertainty in the research is the variability in results, noting that findings were mixed across different studies and indications.


Q: Is it possible to be allergic to ingredients in Vegestabil?

Official documents strictly prohibit (contraindicate) the use of Vegestabil for individuals with known hypersensitivity to either of the active ingredients, Dipotassium Clorazepate or Sulpiride.


Q: What types of patients were studied in the main research for Vegestabil?

The majority of research evidence focuses on patterns observed in studies involving young, healthy adults experiencing self-described mild-to-moderate stress or low mood, or mild sleep issues. The official documentation notes that data for certain groups, such as older adults, remain insufficient.


Q: What are the key findings from the clinical trials for Vegestabil?

Key themes described in the official research overview include patterns of small-to-moderate differences on self-reported mood scores compared to a control group. Participants also often reported improvements in perceived quality of sleep over the short study durations.


Q: Are there different strengths or forms (e.g., tablet, liquid) of Vegestabil?

Vegestabil is an Oral dosage form presented as Comprimidos (Tablets). Regulatory documents indicate that dosing is initiated at a low starting dose and can be adjusted up to a maximum authorized dose, reflecting the availability of different strengths. No other forms, such as liquid, are listed.


Q: Why do official materials recommend careful use with other medicines that affect the central nervous system?

Caution is officially recommended because using Vegestabil with other medicines that affect the Central Nervous System (CNS depressants), such as Opioids or other benzodiazepines, can result in an additive depressant effect. This combined action can increase the risks associated with sedation.


Q: How can I tell if a side effect from Vegestabil is serious?

Official documentation classifies rare but significant documented risks as Serious Adverse Reactions. These include specific risks such as Neuroleptic Malignant Syndrome (NMS), QT interval prolongation (a heart rhythm issue), and severe respiratory depression. Official guidance instructs that if a patient experiences highly unusual or life-threatening symptoms, a healthcare professional should be consulted.


Q: What are common symptoms that indicate Vegestabil is effective?

The drug's general purpose is to provide an integrated approach for managing pronounced psychological tension and associated states of excessive anxiety. Effectiveness is linked to the drug's action in promoting Central Nervous System relaxation and helping to reduce the mental and physical hyperactivity linked to profound worry.


Q: Does the time of day matter when taking Vegestabil?

Official administration principles allow the daily dose to be taken once daily or divided throughout the day. It is noted that the medication is often taken at bedtime to align with the sedative properties of the anxiolytic component.

How should Vegestabil be stored and disposed of?

Vegestabil tablets must be stored strictly according to official regulatory guidelines to maintain potency and safety. The product requires storage at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F), with storage above 25 C or freezing being prohibited environments.

Required Conditions

  • Keep the medication in its original container and ensure the container is tightly closed.
  • The tablets must be protected from light and moisture.
  • Keep out of the sight and reach of children and store securely due to the controlled substance component.
  • Do not keep outdated medicine. For disposal of unused or expired tablets, official guidance is to consult a healthcare professional or pharmacist.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Vegestabil found in:

A-Z Index: